A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis.

Trial Profile

A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2009

At a glance

  • Drugs Dirucotide (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms MAESTRO-03
  • Most Recent Events

    • 18 Aug 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 27 Jul 2009 Status changed from recruiting to discontinued based on results of the MAESTRO-01 trial (see trial profile 700008236), according to an Eli Lilly media release.
    • 07 Jul 2009 Planned end date changed from 1 Jun 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top